pharmaceuticals
Global biosimilars market to hit $72.3b by 2035
Global biosimilars market to hit $72.3b by 2035
Thanks to the rising number of regulatory approvals.
India’s rising obesity cases open market opportunities for drugmakers
Diagnosed prevalent cases are expected to increase to 14.63 million in 2031.
India’s pharma industry to face ongoing scrutiny over quality issues
A recent FDA announcement presents risks for the country’s sector.
China’s biopharma sector strikes $30b in oncology licensing deals
Antibody-drug conjugates dominated licensing activity in 2024.
Global radiopharmaceuticals market to be valued at $12.2b by 2030
Its growth is attributed to a rise in cancer and cardiovascular diseases.
7MM HIV market to be valued at $32.1b by 2033
Thanks to the increased uptake of long-acting injectable therapies.
APAC’s price controls, tendering processes pose risks to pharma firms
Such practices could impact revenues and market access.
APAC’s HTA adoption to grow amidst infrastructure, talent challenges
Key markets include Indonesia, the Philippines, and Australia.
Oral proteins and peptides market to hit $24b by 2030
Its expansion is attributed to the prevalence of chronic diseases like diabetes.
7MM COPD market to hit $30.2b in 2033
Triple therapy inhalers are expected to account for 11.3% of the total market.
Japan’s 10-year fund to boost pharmaceutical landscape
The country’s ageing population is driving demand for innovative treatments.
Saudi Arabia’s pharmaceutical market to hit $16.7b by 2029
Thanks to rising investments and increased international collaboration.
South Korea, China lead degrader-antibody conjugate development: report
Companies from these countries collectively account for 19 out of 28 assets worldwide.
India’s pharmaceutical market to reach $41.4b by 2029
This expansion is supported by ongoing public sector efforts.
Personalised medicine outsourcing market to reach $223.69b by 2030
One key driver is the need for specialised expertise.
Global transmucosal drugs market to be valued at $28b by 2032
Thanks to the rising prevalence of chronic conditions.
APAC to boost pharmaceutical growth with increased R&D investments
South Korea allocated 5.2% of its GDP to R&D in 2024.
Most Read
1. Singapore’s AI tool analyses heart attack damage within one minute 2. How can Asia-Pacific prove medical research is worth the money? 3. Medical Taiwan 2026 closes with $168.7m in business opportunities 4. Obesity drains $45b annually from Australia’s economy 5. India’s medical devices sector set for decade of steady growthResource Center
Read Here
Advertise
Sign Up
Partner Events
Event News
Demand was strong for AI-driven and digital healthcare solutions.
Commentary
Beyond symptom control: Redefining IMID care in Malaysia
How decentralised clinical trials can unlock Asia's research potential